TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10936117

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg once daily (qd)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg twice daily (bid)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (either qd or bid)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (both regimens) during 54 weeks of open-label treatment
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo (bid)
Number of subjects: 253
Study: 8880273

Group type: EXPERIMENTAL
Intervention: Use of Electronic Medical Dossier (EMD)
Number of subjects: 0
Study: 1560164

Group type: EXPERIMENTAL
Intervention: 50 micrograms of inhaled salmeterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 micrograms of inhaled salmeterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 micrograms of inhaled salbutamol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2411079

Group type: EXPERIMENTAL
Intervention: 40 mg acetylsalicylic acid daily for 24 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo daily for 24 weeks
Number of subjects: 16
Study: 31343446

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (20 U frontal, 20 U glabellar, with/without 24 U in crow's feet)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 29654112

Group type: EXPERIMENTAL
Intervention: 60 Hz stimulation of the subthalamic nucleus (STN)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 130 Hz stimulation of the subthalamic nucleus (STN)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Deep brain stimulation off
Number of subjects: 11
Study: 26748531

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Physical Activity (PA)
Number of subjects: 112
Study: 25348013

Group type: EXPERIMENTAL
Intervention: Total Worker Health™ program, implemented through monthly 2-hour peer-led meetings.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 160
Study: 22964967

Group type: EXPERIMENTAL
Intervention: Estrogen (17β‐estradiol 1 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (healthy postmenopausal women)
Number of subjects: 62
Study: 19921145

Group type: EXPERIMENTAL
Intervention: Physiotherapeutic group training including gait and balance exercises with function‐orientated strengthening (twice weekly over 12 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 71
Study: 16900354

Group type: EXPERIMENTAL
Intervention: Humerus intramedullary nail (IMN)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Dynamic compression plate (DCP)
Number of subjects: 47
Study: 16170945

Group type: EXPERIMENTAL
Intervention: Wide-angle visual flow display
Number of subjects: 16

Group type: COMPARATOR
Intervention: Full view display
Number of subjects: 16

Group type: COMPARATOR
Intervention: 20 degrees x 20 degrees central field omission
Number of subjects: 16

Group type: COMPARATOR
Intervention: 105 degrees area display
Number of subjects: 16
Study: 12068250

Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg in juice)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (juice alone)
Number of subjects: 20
Study: 10492633

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 8559203

Group type: EXPERIMENTAL
Intervention: Ragweed-extract immunotherapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 2201731

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7281952

Group type: EXPERIMENTAL
Intervention: Porcine dermis
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional paste bandaging
Number of subjects: 26
Study: 30838896

Group type: EXPERIMENTAL
Intervention: Small head metal-on-metal (SHMoM) THA
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional metal-on-polyethylene (MoP) THA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both SHMoM and MoP THA
Number of subjects: 56
Study: 30256061

Group type: EXPERIMENTAL
Intervention: Taxane-based chemotherapy (4 to 6 cycles)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anthracycline-based chemotherapy (4 to 6 cycles)
Number of subjects: 100
Study: 28811009

Group type: EXPERIMENTAL
Intervention: Sugammadex group (Group S) received rocuronium 0.6 mg/kg at anesthesia induction and sugammadex 2 mg/kg at skin incision.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional anesthesia group (Group C) did not receive any NMBA.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups (Group S and Group C) during facial nerve stimulation.
Number of subjects: 50
Study: 26054147

Group type: EXPERIMENTAL
Intervention: Microinjection acupuncture (MIA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture drug anesthesia (ADA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 24122908

Group type: EXPERIMENTAL
Intervention: TRV130 (0.15 to 7 mg administered intravenously over 1 hour)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRV130 (1.5 mg administered as 30, 15, 5, and 1 minute infusions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRV130 (2.2, 4, and 7 mg doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRV130 (7 mg dose)
Number of subjects: 0
Study: 21766228

Group type: EXPERIMENTAL
Intervention: GTP (500 mg GTP/day)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (60 min/session, three sessions/week)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: GTP + Tai Chi
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo (500 mg starch/day)
Number of subjects: 171
Study: 19156563

Group type: EXPERIMENTAL
Intervention: Self-administered psychotherapeutic tool
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15
Study: 17898246

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) rehydration
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (age-, gender-, and weight-matched children without dehydration)
Number of subjects: 36
Study: 15135261

Group type: EXPERIMENTAL
Intervention: 15 ml of linseed oil (rich in ALA) per day (n=60)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 15 ml of safflower oil (rich in LA) per day (n=30)
Number of subjects: 90
Study: 11684550

Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dalteparin (low-molecular-weight heparin)
Number of subjects: 0
Study: 9610754

Group type: COMPARATOR
Intervention: Growth hormone (GH) replacement therapy, mean dose 0.23 ± 0.01 IU/kg/week, divided into daily subcutaneous injections, for 3 years.
Number of subjects: 20
Study: 8021731

Group type: COMPARATOR
Intervention: Doxorubicin alone (60 mg/m2 i.v. every 3 weeks for eight courses)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus cyclophosphamide (500 mg/m2 i.v. every 3 weeks for eight courses)
Number of subjects: 356
Study: 2510460

Group type: EXPERIMENTAL
Intervention: Stepwise increased hMG dosage (group 1)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High dose hMG for 2 days followed by constant daily dose (group 2)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Both groups (group 1 and group 2)
Number of subjects: 58
Study: 113803

Group type: EXPERIMENTAL
Intervention: Zimelidine 200 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline 150 mg/day
Number of subjects: 0
Study: 31354255

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once daily for 12 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Roflumilast 250 μg once daily for 4 weeks, then 500 μg for 12 weeks (dose-escalation)
Number of subjects: 55
Study: 28291062

Group type: EXPERIMENTAL
Intervention: Pulsed CO2 laser
Number of subjects: 240

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 240
Study: 25588782

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Lactobacillus rhamnosus GG, Bifidobacterium lactis, and Lactobacillus acidophilus, 200 g/day
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pasteurised yogurt (placebo)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 72
Study: 24035102

Group type: EXPERIMENTAL
Intervention: Methadone users during the 'stand-up' test
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy volunteers during the 'stand-up' test
Number of subjects: 3

Group type: COMPARATOR
Intervention: Patients with congenital long QT syndrome (LQTS) during the 'stand-up' test
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Methadone users
Number of subjects: 3
Study: 22185725

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray at 200 μg once daily for 12 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Clarithromycin tablet at 250 mg once daily for 12 weeks
Number of subjects: 43
Study: 19523618

Group type: EXPERIMENTAL
Intervention: GnRH antagonist multiple‐dose protocol (MDP) with OCP pretreatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: GnRH agonist low‐dose long protocol (LP)
Number of subjects: 82
Study: 17050637

Group type: EXPERIMENTAL
Intervention: PES (polyelectrolyte-modified polyethersulphone)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PSU (polysulphone)
Number of subjects: 8
Study: 15858956

Group type: EXPERIMENTAL
Intervention: LC‐PUFA supplementation (LF)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Control (CF)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Breastfed (BF)
Number of subjects: 474
Study: 12808614

Group type: EXPERIMENTAL
Intervention: Neoral cyclosporin (15 mg per kg per day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Tacrolimus (0.2 mg per kg per day)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Neoral cyclosporin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 102
Study: 10639695

Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8560050

Group type: EXPERIMENTAL
Intervention: Clonidine (3 micrograms/kg orally 90-120 min before surgery)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg intravenous 1 min before EIT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 1911017

Group type: EXPERIMENTAL
Intervention: Cisapride and ranitidine administered simultaneously
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine alone
Number of subjects: 12
Study: 7323704

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass surgery with a 3:1 or 1:3 jejunoileal ratio
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (before surgery)
Number of subjects: 34
Study: 30355090

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1441
Study: 26402730

Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA) 3.2 g/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (Olive oil 4 g/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (CLA and Placebo)
Number of subjects: 28
Study: 24290738

Group type: EXPERIMENTAL
Intervention: Imageless navigation system
Number of subjects: 130

Group type: COMPARATOR
Intervention: Freehand conventional technique
Number of subjects: 130
Study: 22552265

Group type: EXPERIMENTAL
Intervention: R1663 (300 mg twice daily or 400 mg once daily for seven days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: R1663
Number of subjects: 48
Study: 20487575

Group type: EXPERIMENTAL
Intervention: Yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1
Number of subjects: 142

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 142
Study: 18407321

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 141

Group type: COMPARATOR
Intervention: Phenprocoumon
Number of subjects: 141

Group type: COMPARATOR
Intervention: Acenocoumarol
Number of subjects: 141
Study: 15693860

Group type: EXPERIMENTAL
Intervention: Liquid paraffin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 40
Study: 11994054

Group type: EXPERIMENTAL
Intervention: entacapone 200 mg four times daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 10048102

Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patches
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 14 mg nicotine patches
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patches
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All treatment conditions
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Smokers under age 30
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Smokers 30 years or older
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Confirmed continuous quitters
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Continuous abstainers surveyed
Number of subjects: 63
Study: 7669957

Group type: EXPERIMENTAL
Intervention: Transesophageal atrial pacing (TAP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gallamine (40 mg intermittent bolus)
Number of subjects: 50
Study: 2185293

Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6119104

Group type: EXPERIMENTAL
Intervention: Conventional propranolol (160 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sustained release oxprenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Long acting propranolol
Number of subjects: 12
Study: 30810976

Group type: EXPERIMENTAL
Intervention: Fire-needle therapy once weekly for 4 weeks plus Oral Huoxue Jiedu Decoction and vaseline cream
Number of subjects: 151

Group type: COMPARATOR
Intervention: Oral Huoxue Jiedu Decoction and vaseline cream
Number of subjects: 151
Study: 28548626

Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine
Number of subjects: 0
Study: 25732161

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC; paclitaxel 175 mg/m(2) over 3 hours and carboplatin AUC 5 mg/mL/min on day 1, repeated every 3 weeks)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Paclitaxel plus cisplatin (TP; paclitaxel 135 mg/m(2) over 24 hours on day 1 and cisplatin 50 mg/m(2) on day 2, repeated every 3 weeks)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC)
Number of subjects: 253
Study: 23632051

Group type: EXPERIMENTAL
Intervention: Intraarticular steroid injections
Number of subjects: 56

Group type: COMPARATOR
Intervention: Radiofrequency denervation
Number of subjects: 56
Study: 21967070

Group type: EXPERIMENTAL
Intervention: Collagenase 0.58 mg injections
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 299
Study: 19147374

Group type: EXPERIMENTAL
Intervention: Elastic taping (Kinesio Tex)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo taping (3M Micropore tape)
Number of subjects: 17
Study: 17107257

Group type: EXPERIMENTAL
Intervention: Sertraline (25 mg/day)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Continuous dosing of sertraline
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Symptom-onset dosing of sertraline
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 14612478

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (100 microg/kg and 10 microg/kg per hour) for 7 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo infusion for 7 days
Number of subjects: 150
Study: 11113047

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention in patients with renal failure
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control group (patients with normal renal function)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Long-term outcomes in renal failure patients
Number of subjects: 362

Group type: COMPARATOR
Intervention: Long-term outcomes in control group (age- and sex-matched)
Number of subjects: 362
Study: 8636558

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 116
Study: 1637970

Group type: EXPERIMENTAL
Intervention: Tree-structured relative risk estimates for censored survival data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tree-structured survival methods proposed by Davis and Anderson
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tree-structured survival methods proposed by Therneau, Grambsch, and Fleming
Number of subjects: 0
Study: 6380335

Group type: EXPERIMENTAL
Intervention: Continuous glucose-insulin-potassium (GIK) infusion for at least 4 hours after surgery
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Continuous glucose-insulin-potassium (GIK) infusion
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-GIK treatment
Number of subjects: 33
Study: 30943227

Group type: EXPERIMENTAL
Intervention: Gummy candy containing 50 mg of ubiquinol, twice daily for 8 weeks
Number of subjects: 40
Study: 28176893

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone combination (SFC)
Number of subjects: 510
Study: 25523837

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg·kg(‐1) iv (Group D)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 141
Study: 23974384

Group type: EXPERIMENTAL
Intervention: Recruitment strategy incorporating patient feedback
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Patient feedback on reasons for trial refusal
Number of subjects: 540
Study: 20801464

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75-300 mg/d)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Fluoxetine (20-60 mg/d)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER and Fluoxetine
Number of subjects: 259
Study: 19841299

Group type: EXPERIMENTAL
Intervention: Iloprost 1 ng kg(‐1) min(‐1) administered intravenously 30 to 90 minutes before and ending 4 hours after the procedure
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo administered intravenously 30 to 90 minutes before and ending 4 hours after the procedure
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 208
Study: 17078183

Group type: EXPERIMENTAL
Intervention: Short-term inpatient care
Number of subjects: 6614

Group type: EXPERIMENTAL
Intervention: Long-term inpatient care
Number of subjects: 6614

Group type: EXPERIMENTAL
Intervention: High costs for hospital care
Number of subjects: 6614

Group type: EXPERIMENTAL
Intervention: High costs for nursing home care
Number of subjects: 6614
Study: 14745710

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 79
Study: 11728949

Group type: EXPERIMENTAL
Intervention: Bgl II polymorphism of the alpha2beta1 integrin gene
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Bgl II+ allele of the alpha2beta1 integrin
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Age, duration of diabetes, BMI, and HbA(1c) level
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Bgl II polymorphism of the alpha2beta1 integrin gene and Apa I polymorphism of the platelet GPIIIa gene
Number of subjects: 234
Study: 9613374

Group type: EXPERIMENTAL
Intervention: Reoperation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Botulinum toxin injection
Number of subjects: 47
Study: 8296736

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 94
Study: 2487463

Group type: EXPERIMENTAL
Intervention: Single-dose oral amoxicillin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Single-dose TMP-SMX (2 tablets DS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Single-dose ofloxacin (400 mg)
Number of subjects: 50
Study: 1105693

Group type: EXPERIMENTAL
Intervention: Intra-amniotic injection of 2.5 mg of 15(S)-15-methyl-prostaglandin F2alpha
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 15(S)-15-methyl-prostaglandin F2alpha (200 mug initially and 300 mug every third hour until 30 hrs or abortion)
Number of subjects: 55
Study: 31301741

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (twice a week for 60 minutes over 6 months)
Number of subjects: 219
Study: 29051218

Group type: EXPERIMENTAL
Intervention: Highest quartile of glucose/GA ratio
Number of subjects: 3026

Group type: COMPARATOR
Intervention: Lowest quartile of glucose/GA ratio
Number of subjects: 3026
Study: 26618460

Group type: EXPERIMENTAL
Intervention: BoNT‐A (Speywood Unit; s.U) and HA fillers
Number of subjects: 0
Study: 23467108

Group type: EXPERIMENTAL
Intervention: Tube cecostomy (Group A)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Loop colostomy (Group B)
Number of subjects: 156
Study: 22241951

Group type: COMPARATOR
Intervention: Insulin-stimulated endothelial function in patients with systolic heart failure
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Insulin-stimulated endothelial function in healthy controls
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Insulin-stimulated endothelial function in patients with both heart failure and diabetes
Number of subjects: 59

Group type: COMPARATOR
Intervention: Forearm glucose uptake in patients with heart failure
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Forearm glucose uptake in patients with both heart failure and diabetes
Number of subjects: 59
Study: 17629442

Group type: EXPERIMENTAL
Intervention: Disulfiram (DSF)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 100